BNT162b2

COVID-19 candidate vaccine

Phase of research

Emergency use authorization

How it helps

Vaccine

Drug status

Experimental

33
Supporting references
0
Contradictory references
18
Clinical trials

General information

BNT162b2 is a candidate vaccine being developed by BioNTech/Pfizer. It is an mRNA type of candidate vaccine based on the RNA platform. Currently, this COVID-19 candidate vaccine is in clinical evaluation. Data from phase I/II clinical trials showed BNT162b1's immunogenicity and transient mild to moderate adverse effects only (Mulligan et al., 2020). On November 9, 2020, Pfizer and BioNTech announced that this vaccine candidate was found to be more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection in the first interim efficacy analysis from phase 3 study. 

On December 2, 2020, the COVID-19 mRNA vaccine BNT162b2 received an emergency use authorization in the UK, and further regulatory decisions across the globe are expected. On December 9, 2020, the vaccine received conditional authorization in Canada. On December 11, 2020, the U.S. FDA issued an emergency use authorization, allowing the Pfizer-BioNTech COVID-19 Vaccine to be distributed in the U.S. On December 21, 2020, the BNT162b2 vaccine was granted conditional marketing authorization by the European Commission following the European Medicines Agency's recommendation, making it available for all EU member states. 

A mass vaccination program is underway, starting on December 8, 2020, in the UK, with many countries following.

On March 31, 2021, Pfizer/BioNTech announced positive topline results of pivotal COVID-19 vaccine study in adolescents. In participants aged 12-15 years old, BNT162b2 demonstrated 100% efficacy and robust antibody responses, exceeding those reported in trial of vaccinated 16-25 year old participants in an earlier analysis, and was well tolerated.

 


Synonyms

BNT162b


Marketed as

COMIRNATY®


Supporting references

Link Tested on Impact factor Notes Publication date DB entry date
Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers - Eight U.S. Locations…
cohort study mixed substance Spike protein RNA
Frontline/healthcare workers 13.61

(Analyses pooled with mRNA-1273.) Standard two-dose regimen of mRNA vaccination in a real-world setting among healthcare-frontline workers displayed 90% effectiveness in preventing SARS-CoV-2 infection (≥14 days after second dose). A single dose administration showed 80% effectiveness (≥14 days after first dose, prior to second dose). Sample size: 2.479 (two doses) + 477 (single dose) + 994 control.

Apr/02/2021 Apr/05/2021
Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2
cohort study mixed substance in vitro RNA
in vitro binding assay; sera of vaccinated individuals 36.13

After a single dose administration, individuals with past SARS-CoV-2 infection developed anti-Spike IgG levels and capacity to inhibit ACE2-binding similar to those without previous SARS-CoV-2 infection after two doses. Sample size: 1,090 (of which 35 were infected in the past and received a single vaccine dose and 228 were not previously infected and received two vaccine doses). Dosage: One or two standard doses.


Apr/01/2021 Apr/13/2021
Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine
cohort study mixed substance Spike protein RNA
Vaccinated subjects (16+ years of age) 36.13

A significant reduction in the mean viral loads was noted in vaccinated individuals who got infected with SARS-CoV-2. The reduction was observed starting on day 12 post 1st dose administration. These results suggest reduced infectivity even in the vaccinated individuals positive for SARS-CoV-2.
Sample size: 4,938. Dosage: Two standard doses (analyses beginning with the 1st dose administration). Primary outcome: Average RT-PCR Ct values.


Mar/29/2021 Apr/08/2021
Anti-SARS-CoV-2 antibodies induced in breast milk after Pfizer-BioNTech/BNT162b2 vaccination
mixed substance case series RNA
Breast milk of vaccinated individuals 6.50

Two weeks after the first vaccine dose administration, increased anti-Spike (SARS-CoV-2) IgA titres were observed in breast milk. Although decline was noted 40+ days after the first dose (therefore, after the second dose administration), the titres were still high above baseline. Similarly, IgG anti-Spike titres were elevated in breast milk, but antibody titres for this class did not decline within the observation period. Sample size: 5 donors. Dosage: Standard vaccination regimen.


Mar/26/2021 Apr/13/2021
Single dose of a mRNA SARS-CoV-2 vaccine is associated with lower nasopharyngeal viral load among nursing home residents with asymptomatic COVID-19
cohort study mixed substance Spike protein RNA asymptomatic
Asymptomatic COVID-19 patients. 8.31

The mean viral load as measured by RT-PCR on a nasopharyngeal swab sample in asymptomatic COVID-19 patients vaccinated with a single dose 12–15 days prior to the virus detection was 2.4-fold lower compared to asymptomatic non-vaccinated patients. The vaccination was therefore hypothesized to lower transmissibility of the virus even in positive (asymptomatic) individuals. Sample size: 5 + 5 control (SARS-CoV-2 positive). Dosage: All cases detected after a single immunization. Primary outcome: Nasopharyngeal viral load.



Mar/26/2021 Mar/31/2021
The effect of SARS-CoV-2 D614G mutation on BNT162b2 vaccine-elicited neutralization
mixed substance in vitro RNA animal model
Sera from immunized mice, rhesus macaques, and humans; SARS-CoV-2 D614 or G614 5.70

A difference in neutralizing capacity of antibodies from sera of vaccinated mice, non-human primates, and human subjects against SARS-CoV-2 D614 and G614 was detectable, but the difference was only modest.

Mar/25/2021 Mar/31/2021
mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection
cohort study mixed substance Spike protein in vitro RNA
Sera of (non)vaccinated convalescent and vaccinated naïve donors; SARS-CoV-2 Spike Wuhan-Hu-1 and B.1.31 pseudoviruses 41.85

(Data pooled with those for <a href=

Mar/25/2021 Mar/31/2021
Immunogenicity of the BNT162b2 vaccine in frail or disabled Nursing Home residents: COVID‐A Study
cohort study elderly in vitro mixed substance RNA Spike protein
Elderly 4.18

The vaccine was safe and elicited an immune response in elderly nursing home residents. The antibody titres were higher in those with previous COVID-19 infection. The vaccine is suggested for use irrespective of frailty and disability profiles. Sample size: 134. Dosage: 2 regular doses.

Mar/25/2021 Mar/31/2021
COVID-19 vaccine response in pregnant and lactating women: a cohort study
cohort study RNA
pregnant and lactating women 6.50 2019

COVID-19 mRNA vaccines generated robust humoral immunity in pregnant and lactating women, with immunogenicity and reactogenicity similar to that observed in non-pregnant women. Vaccine-induced immune responses were significantly greater than the response to natural infection. Immune transfer to neonates occurred via placenta and breastmilk.

Mar/25/2021 Apr/01/2021
Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort
mixed substance Spike protein non-randomized controlled open trial RNA
Patients with chronic inflammatory conditions and immunosuppressive therapy 16.10

A pooled analysis with <a href=

Mar/24/2021 Mar/30/2021
Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases
cohort study mixed substance Spike protein RNA
SARS-CoV-2-naïve patients with rheumatic and musculoskeletal diseases 16.10

(Analyses pooled with mRNA-1273.) Generally, patients with rheumatic or musculoskeletal diseases developed antibody responses after standard vaccination. Only patients on mycophenolate or rituximab therapies were statistically significantly less likely to develop an antibody response. Sample size: 123. Dosage: Standard two-dose regimen.

Mar/23/2021 Apr/03/2021
BNT162b2 mRNA Covid-19 Vaccine Effectiveness among Health Care Workers
cohort study mixed substance Spike protein RNA
Healthcare workers 74.70

During the vaccination campaign, a marked decrease of COVID-19 incidence among healthcare workers was observed, which contrasts with epidemiologic data in general population. The decrease seems to be temporally correlated with the progress of the vaccination campaign among the healthcare workers. Sample size: 6680. Dosage: Standard two-dose regimen.


Mar/23/2021 Apr/03/2021
Antibody Responses after a Single Dose of SARS-CoV-2 mRNA Vaccine
cohort study mixed substance Spike protein RNA Nucleocapsid protein
Sera of single-dose vaccinated health care workers with/without COVID-19 infection history. 74.70

3 weeks after a single dose administration, the subjects without history of SARS-CoV-2 infection displayed significant increase in anti-S1, anti-S2, and anti-RBD (of Spike protein) antibody titres, yet the titres were lower compered to the subject with recently (30–60 days before vaccination) laboratory-confirmed infection or those with prior antibody levels indicating positive infection history. The anti-nucleocapsid antibody levels were not changed by the vaccination, which is in line with the vaccine design (encoded modified Spike protein serving as the immunogen). Sample size: 152 without past confirmed SARS-CoV-2 infection (6 of which with possible undiagnosed infection) + 36 with confirmed past SARS-CoV-2 infection. Dosage: A single dose. Primary outcome: Antibody responses.



Mar/23/2021 Apr/03/2021
Early Evidence of the Effect of SARS-CoV-2 Vaccine at One Medical Center
cohort study mixed substance Spike protein RNA
Frontline healthcare workers 74.70

(Data pooled with mRNA-1273.) A radical decrease in SARS-CoV-2 infection rate was observed in a cohort of vaccinated medical centre employees. It was lower compared not only to the non-vaccinated staff but also to the projected rate based on infection rate trends. The infection rates among employees who had received two vaccine doses, one vaccine dose, and no vaccine dose were 0.05%, 1.82%, and 2.61%, respectively. The overall infection rate during the observed period was 1.5%. Sample size: 23,234 of which 59% received the first dose and 30% received the second.

Mar/23/2021 Apr/03/2021
SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies
antibody in vitro mixed substance peptide RNA small molecule Spike protein
Caco-2 cells; Vero cells; Sera of vaccinated individuals; (VSV) SARS-CoV-2 Spike-pseudotyped virus (WT, B.1.1.7, B.1.351, ant P.1 variants) 38.64

The sera of most of the vaccinated individuals manifested decreased neutralizing activity against SARS-CoV-2 Spike B.1.351 and P.1 variants. This indicates that the vaccine might provide less robust protection from the infection by viruses of the corresponding strains. The neutralizing capacity at lower tested serum dilutions was present and provided complete neutralization, however. The neutralization of B.1.1.7 was reduced only slightly.

Mar/20/2021 Apr/05/2021
Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity
mixed substance in vitro RNA
in vitro binding assay; sera of vaccinated individuals; 293T-ACE2 cells; SARS-CoV-2 Spike pseudovirus (various variants) 38.64

SARS-CoV-2 Spike protein of some strains, especially of B.1.351 (“South Africa”), seems to be several-fold more resistant to neutralization by antibodies from vaccinated subjects compared to the wild type virus. This is especially true for individuals with a single dose vaccination without prior SARS-CoV-2 infection or exposure. The sera of subjects vaccinated with two doses, or of those with previous virus exposure, seem to retain neutralizing capacity to some extent, however.

Mar/12/2021 Mar/26/2021
Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies
biophysical assay cohort study in vitro mixed substance RNA Spike protein
In vitro binding assay; in vitro biophysical assay; sera of vaccinated older adults; HEK293T/17 cells; (HIV-1) SARS-CoV-2 Spike (WT or variant) pseudovirus 42.78

Sera of vaccinated older adults included antibodies which retained their neutralizing capacity against SARS-CoV-2 Spike protein variant B.1.1.7 and K417N, E484K, and N501Y triple mutant. However, some decrease in neutralization capacity of the sera against the B.1.1.7 variant was observed. Alarmingly, the neutralizing capacity against the triple mutant was decreased or completely diminished in several antibodies.

Mar/11/2021 Mar/22/2021
Impressive boosting of anti-S1/S2 IgG production in COVID-19-experienced patients after the first shot of the BNT162b2 mRNA COVID-19 Vaccine
cohort study mixed substance Spike protein RNA
Adults vaccinated with a single vaccine dose 8.31

While the neutralizing antibody titres after a single vaccine dose in adults with no COVID-19 infection history did not significantly increase after a single dose administration, the increase in titres of previously infected individuals was statistically and numerically significant. Sample size: 52 (COVID-19-naïve) + 69 (with COVID-19 history). Dosage: A singe dose.


Mar/06/2021 Mar/22/2021
Antibody Response to the BNT162b2 mRNA COVID-19 Vaccine in Subjects with Prior SARS-CoV-2 Infection
mixed substance case series Spike protein RNA
Vaccinated health-care workers 3.82

In individuals who have been infected with SARS-CoV-2 in the past a single dose of the vaccine elicited after 7 days anti-RBD IgG and neutralizing antibody responses similar to the responses in infection-naïve individuals 7 days after the second dose administration. Sample size: 5 with COVID-19 infection history + 9 infection-naïve.

Mar/05/2021 Apr/16/2021
Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2
cohort study mixed substance RNA
Sera of health-care workers vaccinated with a single dose 45.54

At days 7 or 14 after a single-dose vaccination, the health-care workers with prior SARS-CoV-2 infection developed higher anti-Spike antibodies and more potent live virus neutralizing capacity compared to the non-infected subjects. Sample size: 13 with evidence of previous symptomatic SARS-CoV-2 infection + 6 with evidence of previous asymptomatic SARS-CoV-2 infection + 10 seronegative. Data were pooled with <a href=

Mar/01/2021 Mar/16/2021
Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals
cohort study mixed substance RNA
Sera of health-care workers vaccinated with a single dose 60.39

Individuals vaccinated with a single dose had similar levels of anti-Spike (SARS-CoV-2) antibodies to the ones with previous SARS-CoV-2 infection (mild or asymptomatic). Subjects who recovered from SARS-CoV-2 infection and received a single dose of the vaccine had significantly higher anti-Spike titres. Sample size: 24 with evidence of previous SARS-CoV-2 infection + 27 seronegative. Dosage: A single dose. Primary outcome: Immunological response 19–29 (median 22) days post single-dose vaccination.



Feb/25/2021 Mar/16/2021
Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine
cohort study mixed substance RNA
Sera of health-care workers vaccinated with a single dose 60.39

Based on T cell responses, anti-Spike protein antibody titres, and neutralizing antibody titres, it was concluded that individuals who recovered from SARS-CoV-2 infection before administration of the vaccine produced significant immunological response after a single-dose administration. On the other hand, a single vaccination might be insufficient for protection against COVID-19 in some individuals, especially over 50 years of age, who were not infected prior to the vaccination. Sample size: 21 with evidence of previous SARS-CoV-2 infection + 51 infection-naïve. Dosage: A single dose. Primary outcome: Immunological response 21-25 days post single-dose vaccination.


Feb/25/2021 Mar/16/2021
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
cohort study mixed substance Spike protein RNA
Vacciniated individuals of at least 16 years of age. 74.70

The effectivity of the vaccine 14 to 20 days after the first dose administration in preventing documented infection, symptomatic COVID-19, hospitalization, and severe disease was observed to be ca. 46%, 57%, 74%, and 62% respectively. The values at 7 or more days after the second dose were 92%, 94%, 87%, and 92%, respectively. The effectiveness in preventing COVID-19-caused death was estimated to be 72% for days 14 to 20 after the first immunization and 84% at the period starting 7 days after the second dose. Sample size: 596,618 matched pairs.

Feb/24/2021 Mar/04/2021
Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera
cohort study in vitro mixed substance RNA Spike protein viral vector
Sera of vaccinated subjects; SARS-CoV-2 strain SARS-CoV-2/human/AUS/VIC01/2020 (“Victoria”); SARS-CoV-2 B.1.1.7 38.64

Although a 3.3-fold decrease in neutralization titres against B.1.1.7 strain was observed compared to an early Wuhan-related strain, the neutralization remained robust, and no evidence of vaccine escape was observed.

Feb/18/2021 Apr/03/2021
Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients
cohort study mixed substance RNA
Vaccinated health-care workers. 60.39

The infection rate reduction in vaccinated healthcare workers was 30% 1-14 days after the first dose and 75% 15-28 days after the first dose (with 91% of the subjects receiving the second dose on day 21 or 22). Symptomatic infection rate reduction values were 47% and 85% at these time intervals, respectively. Sample size: 7,214 received the first dose of which 6,037 received the second one + 1,895 non-vaccinated.

Feb/18/2021 Mar/07/2021
mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants
mixed substance in vitro RNA cryo-EM
sera of immunized volunteers (the source of antibody-producing B cells); in vitro binding assay; cryo-EM; hACE2-293T cells; HT1080ACE2.cl14 cells; SARS-CoV-2 variant Spike-pseudotyped viruses 42.78

Some of the antibodies identified in the B cells from immunized volunteers which bound SARS-CoV-2 Spike S or BRD domain of the original SARS-CoV-2 were found to have a decreased or no neutralizing activity against some of the emerging Spike variants (E484K or N501Y or the K417N:E484K:N501Y combination). Overall, the plasma neutralizing activity against these variants was present but decreased.

Feb/10/2021 Mar/01/2021
Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera
mixed substance in vitro RNA
Vero E6 cells; vaccinated human sera; SARS-CoV-2 strain USA-WA1/2020 - WT or with modified Spike (N501Y or Δ69/70 + N501Y + D614G or E484K + N501Y + D614G) 36.13

The differences between neutralization titres in sera from vaccinated humans (2 or 4 weeks after the 2nd dose) against modified live SARS-CoV-2 viruses carrying common Spike mutations and titres against the non-mutated form were of a moderate magnitude only (0.81- to 1.41-fold). The lowest value was observed for the E484K + N501Y + D614G combination, which corresponds to the mutations in the so-called

Feb/08/2021 Feb/15/2021
Immunogenic BNT162b vaccines protect rhesus macaques from SARS-CoV-2
mixed substance Spike protein RNA animal model
BALB/c mice; rhesus macaques; SARS-CoV-2 strain USA-WA1/2020 42.78

A single intramuscular dose elicited a strong immune response in mice characterized by a potent TH1 response, prevalent IFNγ-producing CD8+ T-cell response, and higher presence of germinal centre B cells in injection site draining lymph nodes and spleen. Vaccination of rhesus macaques using a prime/boost scheme resulted in SARS-CoV-2 neutralising geometric mean titres 8.2 to 18.2 more potent than those of convalescent COVID-19 patients’ sera. The macaques were protected from viral RNA presence in the lower respiratory tract. No vaccine-induced disease enhancement was observed.

Feb/01/2021 Feb/03/2021
BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
phase I clinical trial phase II clinical trial RNA preprint non-randomized non-controlled open trial
Healthy adults

vaccination with BNT162b2 at well tolerated doses elicits a combined adaptive humoral and cellular immune response, which together may contribute to protection against COVID-19

Dec/11/2020 Jan/04/2021
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
mixed substance randomized controlled double-blind trial phase II clinical trial phase III clinical trial RNA
16+ years old volunteers 74.70

The vaccine displayed 95% efficacy in preventing COVID-19 infection with similar outcomes in all analysed subgroups. The incidence of severe adverse reactions was low and comparable with the placebo group. Sample size: 21,720 +21,728 placebo. Dosage: Two doses of 30 μg 21 days apart.


Dec/10/2020 Dec/16/2020
Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults
phase I clinical trial phase II clinical trial randomized controlled single-blind trial RNA
Patients 42.78

The vaccine of nucleoside-modified RNA encoding receptor-binding domain of the SARS-CoV-2 spike protein delivered via lipid nanoparticles in clinical trial phase I/II displayed immunogenicity. SARS-CoV-2 neutralizing titers and anti-RBD IgG levels increased with dose level and after second dose. Adverse effects were mild to moderate and transient. Second 100 µg dose was not administered. Sample size: 12 (10 µg), 12 (30 µg), 12 (100 µg) + 9 placebo. Dosage: 2 doses of 10 and 30 µg 21 days apart, or a single dose of 100 µg.

Aug/12/2020 Aug/26/2020
Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report
phase I clinical trial phase II clinical trial RNA preprint
healthy adults Jul/01/2020 Jul/03/2020
DRAFT landscape of COVID-19 candidate vaccines – 26 March 2020 in vitro Mar/26/2020 Apr/03/2020

Clinical trials

ID Title Status Phase Start date Completion date
NCT04815031 Drug Use Investigation of COMIRNATY Intramuscular Injection Not yet recruiting Apr/07/2021 Dec/12/2022
NCT04816669 Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Lyophilized Formulation of BNT162b2 Against COVID-19 in Healthy Adults Recruiting Phase 3 Apr/01/2021 May/30/2021
NCT04834869 COVID-19 Vaccines Safety Tracking (CoVaST) Not yet recruiting Apr/01/2021 Jan/31/2022
NCT04805125 Immunocompromised Swiss Cohorts Based Trial Platform Not yet recruiting Phase 3 Apr/01/2021 Jul/01/2022
NCT04816643 Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children <12 Years of Age Recruiting Phase 1 Mar/24/2021 Aug/29/2023
NCT04775069 Antibody Response to COVID-19 Vaccines in Liver Disease Patients Not yet recruiting Phase 4 Mar/15/2021 Mar/31/2022
NCT04824638 BNT162b2 Vaccination With Two Doses in COVID-19 Negative Adult Volunteers and With a Single Dose in COVID-19 Positive Adult Volunteers Recruiting Phase 2 Mar/08/2021 Dec/08/2023
NCT04754594 Study to Evaluate the Safety, Tolerability, and Immunogenicity of SARS CoV-2 RNA Vaccine Candidate (BNT162b2) Against COVID-19 in Healthy Pregnant Women 18 Years of Age and Older Recruiting Phase 2|Phase 3 Feb/16/2021 Jun/27/2022
NCT04713553 A Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Production Lots and Dose Levels of BNT162b2 Against COVID-19 in Healthy Participants Recruiting Phase 3 Feb/15/2021 May/11/2021
NCT04756817 Immunogenicity of the BNT162b2 Covid-19 Vaccine in Elderly People Aged 85 and Older in Greece Recruiting Feb/13/2021 Sep/30/2021
NCT04733807 Antibodies Response to mRNA Vaccine Against Covid-19 Recruiting Jan/28/2021 Feb/01/2022
NCT04743388 Study of the Kinetics of Antibodies Against COVID-19 (SARS-CoV-2) and of Cellular Subpopulations of the Immune System Recruiting Jan/04/2021 Apr/01/2022
NCT04649021 Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy Population Active, not recruiting Phase 2 Dec/04/2020 Dec/01/2021
NCT04588480 Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Japanese Adults Active, not recruiting Phase 1|Phase 2 Oct/21/2020 Nov/30/2021
NCT04537949 A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults Active, not recruiting Phase 1|Phase 2 Sep/09/2020 Feb/01/2022
NCT04523571 Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b1) in Chinese Healthy Subjects Active, not recruiting Phase 1 Jul/28/2020 Aug/01/2021
NCT04368728 Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals Recruiting Phase 2|Phase 3 Apr/29/2020 Apr/06/2023
NCT04380701 A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-2019 in Healthy and Immunocompromised Adults Recruiting Phase 1|Phase 2 Apr/23/2020 Apr/01/2023